| http://www.w3.org/ns/prov#value | - Results from a recent phase II trial demonstrated that blockade of RANKL with denosumab decreased structural damage, including bone erosions, in patients with RA; however, it had no effect on the American College of Rheumatology response criteria, DAS28 (disease activity score using 28 joint counts) criteria, or RA flares [38].
|
